Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.58 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | PLG | P00747 | 1/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24601730 | 0.95 | FOLH1 (0.70) | FOLH1TDP1PRSS1PRSS2PRSS3 | |
| SCHEMBL24601734 | 0.95 | FOLH1 (0.70) | FOLH1TDP1PRSS1PRSS2PRSS3 | |
| SCHEMBL24220333 | 0.93 | FOLH1 (0.68) | FOLH1TDP1PRSS1PRSS2PRSS3 | |
| SCHEMBL24601803 | 0.92 | FOLH1 (0.67) | FOLH1TDP1PRSS1PRSS2PRSS3 | |
| SCHEMBL16408402 | 0.87 | FOLH1 (0.58) | FOLH1TDP1PRSS1PRSS2PRSS3 | |
| SCHEMBL15308981 | 0.87 | F2 (0.73) | FOLH1TDP1PRSS1PRSS2PRSS3 | |
| SCHEMBL30143870 | 0.87 | F2 (0.73) | FOLH1TDP1PRSS1PRSS2PRSS3 | |
| SCHEMBL16082971 | 0.87 | F2 (0.73) | FOLH1TDP1PRSS1PRSS2PRSS3 | |
| SCHEMBL13431904 | 0.87 | F2 (0.73) | FOLH1TDP1PRSS1PRSS2PRSS3 | |
| SCHEMBL18732967 | 0.87 | F2 (0.73) | FOLH1TDP1PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | INDI MOLECULAR, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | INDI MOLECULAR, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | TP53, BAX, RNASE1 | FOLH1 204/4885TDP1 801/4885PRSS1 1069/4885 |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | TP53, BAX, RNASE1 | FOLH1 204/4885TDP1 801/4885PRSS1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.